Piperacillin–tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen)
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Piperacillin–tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen)
Authors
Keywords
-
Journal
BMJ Open
Volume 11, Issue 2, Pages e040210
Publisher
BMJ
Online
2021-02-09
DOI
10.1136/bmjopen-2020-040210
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy
- (2020) Lu Li et al. Frontiers in Pharmacology
- Adjunctive Daptomycin in the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Randomized Controlled Trial
- (2020) Matthew P Cheng et al. CLINICAL INFECTIOUS DISEASES
- Non-adherence in non-inferiority trials: pitfalls and recommendations
- (2020) Yin Mo et al. BMJ-British Medical Journal
- Antibiotics for Ceftriaxone Resistant Gram-Negative Bacterial Bloodstream Infections—Reply
- (2019) Patrick N. A. Harris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Antibiotics for Ceftriaxone-Resistant Gram-Negative Bacterial Bloodstream Infections
- (2019) Jesús Rodríguez-Baño et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The REDCap consortium: Building an international community of software platform partners
- (2019) Paul A. Harris et al. JOURNAL OF BIOMEDICAL INFORMATICS
- Population Pharmacokinetics of Piperacillin in Sepsis Patients: Should Alternative Dosing Strategies Be Considered?
- (2018) Maria Goul Andersen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae
- (2018) Oded Scheuerman et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials
- (2018) Konstantinos Z Vardakas et al. LANCET INFECTIOUS DISEASES
- Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance
- (2018) Patrick N. A. Harris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial
- (2018) Dafna Yahav et al. CLINICAL INFECTIOUS DISEASES
- Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae
- (2017) Zaira Raquel Palacios-Baena et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- MIC-based dose adjustment: facts and fables
- (2017) Johan W Mouton et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Randomized trials addressing a similar question are commonly published after a trial stopped early for benefit
- (2017) M. Hassan Murad et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Comparison Between Carbapenems and β-Lactam/β-Lactamase Inhibitors in the Treatment for Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: A Systematic Review and Meta-Analysis
- (2017) Maged Muhammed et al. Open Forum Infectious Diseases
- A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae
- (2016) Belén Gutiérrez-Gutiérrez et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum β-lactamases
- (2016) A. Isla et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Carbapenem Therapy Is Associated With Improved Survival Compared With Piperacillin-Tazobactam for Patients With Extended-Spectrum -Lactamase Bacteremia
- (2015) P. D. Tamma et al. CLINICAL INFECTIOUS DISEASES
- Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients
- (2015) Eun Kyoung Chung et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Power failure: why small sample size undermines the reliability of neuroscience
- (2013) Katherine S. Button et al. NATURE REVIEWS NEUROSCIENCE
- Population Pharmacokinetics of Extended-Infusion Piperacillin-Tazobactam in Hospitalized Patients with Nosocomial Infections
- (2012) T. W. Felton et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- -Lactam/ -Lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum -Lactamase-Producing Escherichia coli: A Post Hoc Analysis of Prospective Cohorts
- (2011) J. Rodriguez-Bano et al. CLINICAL INFECTIOUS DISEASES
- Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Antibiotic Therapy for Sepsis
- (2010) M. Paul et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept
- (2010) Jason A. Roberts et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Stopping Randomized Trials Early for Benefit and Estimation of Treatment EffectsSystematic Review and Meta-regression Analysis
- (2010) Dirk Bassler JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Killing of Escherichia coli by β-lactams at different inocula
- (2009) Vincent H. Tam et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started